CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 5,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at $350,000. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

CG Oncology Price Performance

NASDAQ:CGON opened at $72.84 on Friday. The company has a market cap of $6.42 billion, a P/E ratio of -31.26 and a beta of 0.31. The firm’s fifty day moving average price is $64.32 and its two-hundred day moving average price is $57.91. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $75.50.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, equities research analysts expect that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock worth $98,093,000 after purchasing an additional 259,311 shares during the period. Stempoint Capital LP bought a new position in CG Oncology in the 1st quarter valued at about $13,916,000. California State Teachers Retirement System increased its holdings in CG Oncology by 23.6% in the 1st quarter. California State Teachers Retirement System now owns 51,499 shares of the company’s stock valued at $3,485,000 after buying an additional 9,841 shares during the period. Royal Bank of Canada raised its position in shares of CG Oncology by 18.6% in the 1st quarter. Royal Bank of Canada now owns 11,439 shares of the company’s stock valued at $774,000 after buying an additional 1,793 shares in the last quarter. Finally, EcoR1 Capital LLC raised its position in shares of CG Oncology by 3.5% in the 1st quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock valued at $74,583,000 after buying an additional 37,200 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CGON shares. Truist Financial restated a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Royal Bank Of Canada lifted their price target on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research note on Monday, May 18th. Finally, Wolfe Research initiated coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.